1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68BC5380C3AD56D1900258A300040EA08
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/rare-blood-disorders-msl-team-excellence-benchmarking-staffing-roles-recruitment-development-retention-field-success?opendocument
18
19opendocument
203.238.180.174
21
22
23best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Field Medical Excellence

Rare Blood Disorders MSL Team Excellence: Benchmarking Staffing, Roles, Recruitment, Development, Retention, and Field Success

ID: POP-367


Features:

26 Info Graphics

25 Data Graphics

280+ Metrics

77 Narratives


Pages: 58


Published: 2023


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Within the realm of Rare Blood Disorders, field medical teams play a pivotal role in nurturing collaborative relationships with influential Healthcare Professionals (HCPs) and Key Opinion Leaders (KOLs). Leading field medical teams are responding to a wave of transformation that necessitates both disruption and innovation in their structural approaches, stakeholder support strategies, and the value they deliver and measure.

Best Practices, LLC conducted benchmarking research to uncover current and emerging trends around managing field-based, hybrid and virtual MSLs in Rare Blood Disorders therapeutic area. The insights presented in this report will assist Rare Blood Disorders field medical leaders in enhancing MSL retention, offering competitive compensation packages, optimizing staffing, deploying effective engagement strategies, facilitating access to critical external experts, and measuring field performance and its far-reaching impact.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Agios; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Astellas; Bayer; BioMarin; Chiesi; CSL Behring; Fresenius Medical Care; Kyowa Kirin; Legend Biotech; Novartis; Novo Nordisk; Servier; Sobi; Takeda Pharmaceuticals; Vertex Pharmaceuticals

Study Snapshot

Best Practices, LLC engaged Field Medical and other Medical Affairs leaders from 17 top Rare Blood Disorders manufacturers in this research through a benchmark survey. Deep-dive interviews were also conducted with field medical leaders to capture additional insights.

Key topics covered in this report include:

  • Rare Blood Disorders Staffing Levels: Traditional MSLs vs. Hybrid MSLs
  • Drivers of Rare Blood Disorders Field Team Evolution
  • Medical vs. Commercial Field Resourcing
  • Effective MSL Recruitment in Rare Blood Disorders Segment: Factors and Tactics
  • MSL Training Areas in Rare Blood Disorders Segment
  • MSL Salary Levels and Trends in Rare Blood Disorders Segment
  • Effective Perks and Retention Strategies in Rare Blood Disorders Therapeutic Area
  • Field Challenges
  • KOL Access - Post Pandemic
  • Customer Engagement Preference
  • Proactive Outreach
  • F2F Meetings: Value and Ideal Mix

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Attrition rate: Overall, Rare Blood field teams have been forced to replace 31% of MSLs due to workforce attrition in the past 12 months. This includes a whopping 42% turnover rate among field-based MSLs!
  • Ease of access: Some 67% of Rare Blood teams report that gaining access to KOLs and physicians in-person has grown more difficult over the past 6 months. Meanwhile, a combined 88% of companies indicate accessing KOLs virtually has been easier or at least the same as before.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 3-19
II.
Evolving Field Team Roles, Staffing & EngagementPg. 20-30
III.
Recruiting & Retaining MSLsPg. 31-44
IV.
Field Medical KPIsPg. 45-57
V.
About Best Practices, LLCPg. 58

    List of Charts & Exhibits

    I. Executive Summary

    • Project background
    • Key study definitions
    • Benchmark study partners - Rare Blood Disorders segment
    • Key takeaways for rare blood disorders manufacturers
    • Rare Blood Disorders executive field performance dashboard
    • Full data summary
    • Field-based vs. hybrid MSLs - Rare Blood Disorders segment
    • F2F vs. virtual interactions - Rare Blood Disorders segment
    • Effective recruitment and retention principles in rare blood disorders segment

    II. Evolving Field Team Roles, Staffing & Engagement

    • Prevalence of MSL types across the industry (Rare Blood Disorders) – Field-based MSLs vs. Hybrid MSLs vs. Virtual MSLs
    • Case study: Large US pharma organization pilot
    • Average staffing levels at Rare Blood Disorders field medical groups
    • Assessing effectiveness of different MSL types in Rare Blood Disorders segment
    • Post-Pandemic drivers of field team evolution
    • Anticipated MSL staffing trends in Rare Blood Disorders segment
    • Average staffing levels for non-MSL field roles in Rare Blood Disorders segment
    • Key field support roles in Rare Blood Disorders therapeutic area
    • Sales rep-to-MSL ratio in Rare Blood Disorders therapeutic area

    III. Recruiting & Retaining MSLs

    • Overall YoY attrition rate among Rare Blood’s field-based MSLs
    • Successful MSL recruitment factors
    • Effective tactics to recruit MSLs in rare blood disorders segment
    • MSL recruitment lessons learned in Rare Blood Disorders segment
    • MSL training for essential field skills in Rare Blood Disorders therapeutic area
    • Average salary levels of Rare Blood Disorders MSLs
    • Drivers of MSL compensation
    • Predicted MSL salary trends
    • Defending increased field team investment
    • Effective perks in attracting new MSLs and retaining existing staff
    • Top MSL retention strategies in Rare Blood Disorders segment

    IV. Field Medical KPIs

    • Top challenges faced by Rare Blood Disorders field teams in supporting external stakeholders
    • Post-Pandemic KOL and HCP access
    • KOL and HCP engagement preferences
    • Average KOL call list size in Rare Blood Disorders segment
    • Total monthly in-person and virtual meetings with KOLs
    • Proactive outreaches to KOLs in Rare Blood Disorders therapeutic area
    • MSL proactivity index
    • Interview narrative around proactive outreach
    • Value of F2F meetings in Rare Blood Disorders MSL scorecard
    • Ideal mix of F2F interactions
    • Interview narratives around top KPIs used to demonstrate Rare Blood field impact
    • Effective KPIs used to measure Rare Blood field impact